{"entity":{"id":"nct06443671","kind":"trial","name":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","aka":["PKUCH-R09"],"tldr":"A phase 2/3 trial of cAPOX (capecitabine, oxaliplatin), fruquintinib and tislelizumab in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.","summary":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer is a phase 2/3, randomised interventional study registered as NCT06443671 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 132 participants, started 2024-06-01 and due to reach its primary completion in 2026-06-01. Interventions recorded: CapeOX; Fruquintinib and Tislelizumab combined with mCapeOX. Conditions listed: Rectal Cancer. Primary outcome: Pathological complete response(pCR) rates. Colorectal eligibility wording from the registry: \"* Histologically confirmed rectal adenocarcinoma; Immunohistochemistry suggests pMMR, or PCR suggests MSS type patients;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06443671","url":"https://clinicaltrials.gov/study/NCT06443671"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","cytotoxic-chemotherapy","kinase-inhibitors","platinum"],"targets":[],"drugs":["capox","fruquintinib","tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06443671","phase":"2/3","setting":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Open-label, Multicenter, Randomized Controlled Trial","sponsor":"Peking University Cancer Hospital & Institute","enrolled":132,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06443671/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}